- Home
- CBU vs APLS Comparison
CBU vs APLS Comparison
Compare CBU & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBU
- APLS
- Stock Information
- Founded
- CBU 1866
- APLS 2009
- Country
- CBU United States
- APLS United States
- Employees
- CBU N/A
- APLS N/A
- Industry
- CBU Major Banks
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CBU Finance
- APLS Health Care
- Exchange
- CBU Nasdaq
- APLS Nasdaq
- Market Cap
- CBU 3.7B
- APLS 4.0B
- IPO Year
- CBU N/A
- APLS 2017
- Fundamental
- Price
- CBU $63.30
- APLS $29.94
- Analyst Decision
- CBU Buy
- APLS Buy
- Analyst Count
- CBU 4
- APLS 18
- Target Price
- CBU $65.25
- APLS $46.59
- AVG Volume (30 Days)
- CBU 249.7K
- APLS 2.1M
- Earning Date
- CBU 01-21-2025
- APLS 02-25-2025
- Dividend Yield
- CBU 2.91%
- APLS N/A
- EPS Growth
- CBU 12.06
- APLS N/A
- EPS
- CBU 3.13
- APLS N/A
- Revenue
- CBU $706,337,000.00
- APLS $715,216,000.00
- Revenue This Year
- CBU N/A
- APLS $95.82
- Revenue Next Year
- CBU $8.71
- APLS $12.02
- P/E Ratio
- CBU $20.22
- APLS N/A
- Revenue Growth
- CBU 10.20
- APLS 162.10
- 52 Week Low
- CBU $41.50
- APLS $24.34
- 52 Week High
- CBU $73.39
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- CBU 51.76
- APLS 43.96
- Support Level
- CBU $61.60
- APLS $27.61
- Resistance Level
- CBU $63.89
- APLS $30.13
- Average True Range (ATR)
- CBU 1.63
- APLS 1.48
- MACD
- CBU 0.35
- APLS -0.46
- Stochastic Oscillator
- CBU 90.51
- APLS 31.45
About CBU Community Bank System Inc.
Community Financial System Inc is a diversified financial services company that is focused on four main business lines banking, benefits administration, insurance services and wealth management. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. Key revenue is generated from banking business.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.